Trial · NCT01441960
Optimal Dose of Succinylcholine and Rocuronium for Electroconvulsive Therapy (ECT)
NCT01441960, Not applicable, Completed, Massachusetts General Hospital; results first posted 2015-06-02
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Optimal Dose of Succinylcholine and Rocuronium for Electroconvulsive Therapy (ECT). Trials, record NCT01441960. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01441960
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Optimal Dose of Succinylcholine and Rocuronium for Electroconvulsive Therapy (ECT)
- NCT number
- NCT01441960
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 45 participants, actual
- Lead sponsor
- Massachusetts General Hospital
- Conditions
- Neuromuscular Blockade, ECT
- Interventions
- Succinylcholine, Rocuronium
- First posted
- 2011-09-28
- Last updated
- 2015-06-02
- Results first posted
- 2015-06-02
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Optimal Dose of Neuromuscular Blocking Agent During ECT | Up to six weeks following inclusion | The optimal dose of muscle neuromuscular blocking is defined as the lowest dose of either compound that predicts 'acceptable' control of muscle strength during ECT. Assessment of the primary end point is based on a dichotomous scale 'acceptable' and 'not acceptable' control of muscle strength during ECT, and the two assessors will be blinded to the dose of neuromuscular blocking agent. The optimal dose was identified for each subject, and results were reported as the average of all lowest doses collected in the study. |
| Secondary | Compound Specific Differences in Time to Recovery From Neuromuscular Blockade | Up to six weeks following inclusion | The investigators defined the compound specific differences in time to recovery from neuromuscular blockade - i.e., recovery of spontaneous breathing and recovery of the twitch height to baseline. |
| Secondary | Differences in Seizure Duration Between Compounds | Up to six weeks following inclusion | Observational reports suggest that differences in seizure duration might exist depending on the neuromuscular blocking agents used to accomplish muscle strength control during ECT. |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Optimal Dose of Neuromuscular Blocking Agent During ECT | Up to six weeks following inclusion | mg.kg-1 | MEAN | |
| SECONDARY | Compound Specific Differences in Time to Recovery From Neuromuscular Blockade | Up to six weeks following inclusion | minutes | MEAN | |
| SECONDARY | Differences in Seizure Duration Between Compounds | Up to six weeks following inclusion | Seconds | MEAN |
Source ClinicalTrials.gov
Results by group6
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Optimal Dose of Neuromuscular Blocking Agent During ECT | NMBA: Sux | 0.85 | 95% Confidence Interval 0.77 to 0.94 | mg.kg-1 | |
| Optimal Dose of Neuromuscular Blocking Agent During ECT | NMBA- Rocuronium | 0.41 | 95% Confidence Interval 0.36 to 0.46 | mg.kg-1 | |
| Compound Specific Differences in Time to Recovery From Neuromuscular Blockade | Succinylchline | 9.7 | Standard Deviation 3.5 | minutes | |
| Compound Specific Differences in Time to Recovery From Neuromuscular Blockade | Rocuronium | 19.5 | Standard Deviation 5.7 | minutes | |
| Differences in Seizure Duration Between Compounds | Succinylcholine | 27 | Standard Deviation 14 | Seconds | |
| Differences in Seizure Duration Between Compounds | Rocuronium | 31 | Standard Deviation 11 | Seconds |
Source ClinicalTrials.gov
Participant flow12
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| First Neuromuscular Blocking Agent: | STARTED | Succinylcholine First, Then Rocuronium | 26 | |
| First Neuromuscular Blocking Agent: | STARTED | Rocuronium First , Then Succinylcholine | 19 | |
| First Neuromuscular Blocking Agent: | COMPLETED | Succinylcholine First, Then Rocuronium | 18 | |
| First Neuromuscular Blocking Agent: | COMPLETED | Rocuronium First , Then Succinylcholine | 13 | |
| First Neuromuscular Blocking Agent: | NOT COMPLETED | Succinylcholine First, Then Rocuronium | 8 | |
| First Neuromuscular Blocking Agent: | NOT COMPLETED | Rocuronium First , Then Succinylcholine | 6 | |
| Second Neuromuscular Blocking Agent | STARTED | Succinylcholine First, Then Rocuronium | 18 | |
| Second Neuromuscular Blocking Agent | STARTED | Rocuronium First , Then Succinylcholine | 13 | |
| Second Neuromuscular Blocking Agent | COMPLETED | Succinylcholine First, Then Rocuronium | 18 | |
| Second Neuromuscular Blocking Agent | COMPLETED | Rocuronium First , Then Succinylcholine | 13 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 participant flowAdverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | NMBA: Succinylcholine | ||
| Total, all-cause mortality | NMBA: Rocuronium | ||
| Total, other adverse events | NMBA: Succinylcholine | 0 | 45 |
| Total, other adverse events | NMBA: Rocuronium | 0 | 45 |
| Total, serious adverse events | NMBA: Succinylcholine | 0 | 45 |
| Total, serious adverse events | NMBA: Rocuronium | 0 | 45 |
Source ClinicalTrials.gov
Papers6
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| NMBA: Succinylcholine vs NMBA: Rocuronium: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01441960
GET https://conductscience.org/api/trials/v1/NCT01441960/registered